恩瑞格（地拉罗司）的服用说明

It is a drug approved to reduce iron burden. The indications of Enrig are:

1. Patients with chronic iron overload transfusion hemosiderinosis secondary to blood transfusion who are 2 years old or older will develop symptoms of chronic iron overload when serum ferritin continues to be >1000 L. At this time, iron chelation therapy should be started.

2. Iron chelators can also be given to patients undergoing ASCT when iron overload occurs.

3. It can be used to treat reversible renal insufficiency caused by Fanconi syndrome.

So, what are the instructions for taking Enrig (deferasirox)?

The recommended starting daily dose of Enrig is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (ie, more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered.

For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered.

In patients who have already responded well to deferoxamine therapy, an initial dose equivalent to half the deferoxamine dose may be considered. Take it on an empty stomach at least 30 minutes before meals, once a day, preferably at the same time every day.

Deferasirox dose adjustment

Myelosuppression: Interrupt treatment; may restart once cause of cytopenias is identified; Contraindicated if platelet count <50,000/mm; Cutaneous Toxicity: Rash (severe): Interrupt treatment; may reintroduce at lower doses (with future dose escalation) and short-term oral corticosteroids.

Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme): Stop and evaluate.

Gastrointestinal: Discontinue treatment for suspected gastrointestinal ulceration or bleeding.

Hearing Loss or Vision Impairment: Consider a reduced dose or treatment interruption.